IBDEI1FA ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,23012,1,4,0)
;;=4^D64.9
;;^UTILITY(U,$J,358.3,23012,2)
;;=^5002351
;;^UTILITY(U,$J,358.3,23013,0)
;;=D75.89^^78^996^3
;;^UTILITY(U,$J,358.3,23013,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23013,1,3,0)
;;=3^Blood & blood forming organ disease, oth spec
;;^UTILITY(U,$J,358.3,23013,1,4,0)
;;=4^D75.89
;;^UTILITY(U,$J,358.3,23013,2)
;;=^5002392
;;^UTILITY(U,$J,358.3,23014,0)
;;=D89.2^^78^996^16
;;^UTILITY(U,$J,358.3,23014,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23014,1,3,0)
;;=3^Hypergammaglobulinemia, unspecified
;;^UTILITY(U,$J,358.3,23014,1,4,0)
;;=4^D89.2
;;^UTILITY(U,$J,358.3,23014,2)
;;=^5002455
;;^UTILITY(U,$J,358.3,23015,0)
;;=E03.9^^78^996^24
;;^UTILITY(U,$J,358.3,23015,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23015,1,3,0)
;;=3^Hypothyroidism, unspecified
;;^UTILITY(U,$J,358.3,23015,1,4,0)
;;=4^E03.9
;;^UTILITY(U,$J,358.3,23015,2)
;;=^5002476
;;^UTILITY(U,$J,358.3,23016,0)
;;=E05.90^^78^996^30
;;^UTILITY(U,$J,358.3,23016,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23016,1,3,0)
;;=3^Thyrotoxicosis w/o thyrotoxic crisis/storm
;;^UTILITY(U,$J,358.3,23016,1,4,0)
;;=4^E05.90
;;^UTILITY(U,$J,358.3,23016,2)
;;=^5002492
;;^UTILITY(U,$J,358.3,23017,0)
;;=E08.42^^78^996^10
;;^UTILITY(U,$J,358.3,23017,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23017,1,3,0)
;;=3^DM d/t underlying condition w/ diabetic polyneuropathy
;;^UTILITY(U,$J,358.3,23017,1,4,0)
;;=4^E08.42
;;^UTILITY(U,$J,358.3,23017,2)
;;=^5002524
;;^UTILITY(U,$J,358.3,23018,0)
;;=E09.42^^78^996^11
;;^UTILITY(U,$J,358.3,23018,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23018,1,3,0)
;;=3^DM drug-induced w/ neurological compl w/ diabetic polyneuropathy
;;^UTILITY(U,$J,358.3,23018,1,4,0)
;;=4^E09.42
;;^UTILITY(U,$J,358.3,23018,2)
;;=^5002566
;;^UTILITY(U,$J,358.3,23019,0)
;;=E10.42^^78^996^4
;;^UTILITY(U,$J,358.3,23019,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23019,1,3,0)
;;=3^DM Type 1 w/ diabetic polyneuropathy
;;^UTILITY(U,$J,358.3,23019,1,4,0)
;;=4^E10.42
;;^UTILITY(U,$J,358.3,23019,2)
;;=^5002606
;;^UTILITY(U,$J,358.3,23020,0)
;;=E10.65^^78^996^5
;;^UTILITY(U,$J,358.3,23020,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23020,1,3,0)
;;=3^DM Type 1 w/ hyperglycemia
;;^UTILITY(U,$J,358.3,23020,1,4,0)
;;=4^E10.65
;;^UTILITY(U,$J,358.3,23020,2)
;;=^5002623
;;^UTILITY(U,$J,358.3,23021,0)
;;=E10.9^^78^996^6
;;^UTILITY(U,$J,358.3,23021,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23021,1,3,0)
;;=3^DM Type 1 w/o complications
;;^UTILITY(U,$J,358.3,23021,1,4,0)
;;=4^E10.9
;;^UTILITY(U,$J,358.3,23021,2)
;;=^5002626
;;^UTILITY(U,$J,358.3,23022,0)
;;=E11.42^^78^996^7
;;^UTILITY(U,$J,358.3,23022,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23022,1,3,0)
;;=3^DM Type 2 w/ diabetic polyneuropathy
;;^UTILITY(U,$J,358.3,23022,1,4,0)
;;=4^E11.42
;;^UTILITY(U,$J,358.3,23022,2)
;;=^5002646
;;^UTILITY(U,$J,358.3,23023,0)
;;=E11.65^^78^996^8
;;^UTILITY(U,$J,358.3,23023,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23023,1,3,0)
;;=3^DM Type 2 w/ hyperglycemia
;;^UTILITY(U,$J,358.3,23023,1,4,0)
;;=4^E11.65
;;^UTILITY(U,$J,358.3,23023,2)
;;=^5002663
;;^UTILITY(U,$J,358.3,23024,0)
;;=E11.9^^78^996^9
;;^UTILITY(U,$J,358.3,23024,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23024,1,3,0)
;;=3^DM Type 2 w/o complications
;;^UTILITY(U,$J,358.3,23024,1,4,0)
;;=4^E11.9
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1FA 3772 printed Sep 23, 2025@19:43:36 Page 2
IBDEI1FA ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,23012,1,4,0)
+2 ;;=4^D64.9
+3 ;;^UTILITY(U,$J,358.3,23012,2)
+4 ;;=^5002351
+5 ;;^UTILITY(U,$J,358.3,23013,0)
+6 ;;=D75.89^^78^996^3
+7 ;;^UTILITY(U,$J,358.3,23013,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,23013,1,3,0)
+10 ;;=3^Blood & blood forming organ disease, oth spec
+11 ;;^UTILITY(U,$J,358.3,23013,1,4,0)
+12 ;;=4^D75.89
+13 ;;^UTILITY(U,$J,358.3,23013,2)
+14 ;;=^5002392
+15 ;;^UTILITY(U,$J,358.3,23014,0)
+16 ;;=D89.2^^78^996^16
+17 ;;^UTILITY(U,$J,358.3,23014,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,23014,1,3,0)
+20 ;;=3^Hypergammaglobulinemia, unspecified
+21 ;;^UTILITY(U,$J,358.3,23014,1,4,0)
+22 ;;=4^D89.2
+23 ;;^UTILITY(U,$J,358.3,23014,2)
+24 ;;=^5002455
+25 ;;^UTILITY(U,$J,358.3,23015,0)
+26 ;;=E03.9^^78^996^24
+27 ;;^UTILITY(U,$J,358.3,23015,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,23015,1,3,0)
+30 ;;=3^Hypothyroidism, unspecified
+31 ;;^UTILITY(U,$J,358.3,23015,1,4,0)
+32 ;;=4^E03.9
+33 ;;^UTILITY(U,$J,358.3,23015,2)
+34 ;;=^5002476
+35 ;;^UTILITY(U,$J,358.3,23016,0)
+36 ;;=E05.90^^78^996^30
+37 ;;^UTILITY(U,$J,358.3,23016,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,23016,1,3,0)
+40 ;;=3^Thyrotoxicosis w/o thyrotoxic crisis/storm
+41 ;;^UTILITY(U,$J,358.3,23016,1,4,0)
+42 ;;=4^E05.90
+43 ;;^UTILITY(U,$J,358.3,23016,2)
+44 ;;=^5002492
+45 ;;^UTILITY(U,$J,358.3,23017,0)
+46 ;;=E08.42^^78^996^10
+47 ;;^UTILITY(U,$J,358.3,23017,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,23017,1,3,0)
+50 ;;=3^DM d/t underlying condition w/ diabetic polyneuropathy
+51 ;;^UTILITY(U,$J,358.3,23017,1,4,0)
+52 ;;=4^E08.42
+53 ;;^UTILITY(U,$J,358.3,23017,2)
+54 ;;=^5002524
+55 ;;^UTILITY(U,$J,358.3,23018,0)
+56 ;;=E09.42^^78^996^11
+57 ;;^UTILITY(U,$J,358.3,23018,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,23018,1,3,0)
+60 ;;=3^DM drug-induced w/ neurological compl w/ diabetic polyneuropathy
+61 ;;^UTILITY(U,$J,358.3,23018,1,4,0)
+62 ;;=4^E09.42
+63 ;;^UTILITY(U,$J,358.3,23018,2)
+64 ;;=^5002566
+65 ;;^UTILITY(U,$J,358.3,23019,0)
+66 ;;=E10.42^^78^996^4
+67 ;;^UTILITY(U,$J,358.3,23019,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,23019,1,3,0)
+70 ;;=3^DM Type 1 w/ diabetic polyneuropathy
+71 ;;^UTILITY(U,$J,358.3,23019,1,4,0)
+72 ;;=4^E10.42
+73 ;;^UTILITY(U,$J,358.3,23019,2)
+74 ;;=^5002606
+75 ;;^UTILITY(U,$J,358.3,23020,0)
+76 ;;=E10.65^^78^996^5
+77 ;;^UTILITY(U,$J,358.3,23020,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,23020,1,3,0)
+80 ;;=3^DM Type 1 w/ hyperglycemia
+81 ;;^UTILITY(U,$J,358.3,23020,1,4,0)
+82 ;;=4^E10.65
+83 ;;^UTILITY(U,$J,358.3,23020,2)
+84 ;;=^5002623
+85 ;;^UTILITY(U,$J,358.3,23021,0)
+86 ;;=E10.9^^78^996^6
+87 ;;^UTILITY(U,$J,358.3,23021,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,23021,1,3,0)
+90 ;;=3^DM Type 1 w/o complications
+91 ;;^UTILITY(U,$J,358.3,23021,1,4,0)
+92 ;;=4^E10.9
+93 ;;^UTILITY(U,$J,358.3,23021,2)
+94 ;;=^5002626
+95 ;;^UTILITY(U,$J,358.3,23022,0)
+96 ;;=E11.42^^78^996^7
+97 ;;^UTILITY(U,$J,358.3,23022,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,23022,1,3,0)
+100 ;;=3^DM Type 2 w/ diabetic polyneuropathy
+101 ;;^UTILITY(U,$J,358.3,23022,1,4,0)
+102 ;;=4^E11.42
+103 ;;^UTILITY(U,$J,358.3,23022,2)
+104 ;;=^5002646
+105 ;;^UTILITY(U,$J,358.3,23023,0)
+106 ;;=E11.65^^78^996^8
+107 ;;^UTILITY(U,$J,358.3,23023,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,23023,1,3,0)
+110 ;;=3^DM Type 2 w/ hyperglycemia
+111 ;;^UTILITY(U,$J,358.3,23023,1,4,0)
+112 ;;=4^E11.65
+113 ;;^UTILITY(U,$J,358.3,23023,2)
+114 ;;=^5002663
+115 ;;^UTILITY(U,$J,358.3,23024,0)
+116 ;;=E11.9^^78^996^9
+117 ;;^UTILITY(U,$J,358.3,23024,1,0)
+118 ;;=^358.31IA^4^2
+119 ;;^UTILITY(U,$J,358.3,23024,1,3,0)
+120 ;;=3^DM Type 2 w/o complications
+121 ;;^UTILITY(U,$J,358.3,23024,1,4,0)
+122 ;;=4^E11.9
